Overview
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Completed
Trial end date:
2015-12-10
2015-12-10
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Genentech, Inc.Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Criteria
Inclusion Criteria:- Histologically or cytologically confirmed adenocarcinoma of the breast, with
measurable or non-measurable locally recurrent or metastatic disease
- Human epidermal growth factor receptor 2 (HER2)-negative and hormone receptor (HR)
(estrogen receptor and/or progesterone receptor)-positive disease as defined by local
guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematologic and end organ function
- Women of childbearing potential must agree to remain abstinent or to use two adequate
methods of contraception, including at least one method with a failure rate of less
than (<) 1 percent (%) per year, during the treatment period and for at least 30 days
after the last dose of study treatment or 6 months after discontinuation of
paclitaxel, whichever is longer
Exclusion Criteria:
- Prior non-capecitabine chemotherapy for locally recurrent or metastatic disease
- Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor for advanced or
metastatic breast cancer
- History of intolerance to a taxane-containing therapy
- History of clinically significant cardiac or pulmonary dysfunction
- History of malabsorption syndrome or other condition that would interfere with enteral
absorption
- Clinically significant history of liver disease
- Active autoimmune disease or active inflammatory disease
- Immunocompromised status due to current known active infection with human
immunodeficiency virus (HIV) or due to the use of immunosuppressive therapies for
other conditions
- Need for current chronic corticosteroid therapy
- Pregnant, lactating, or breastfeeding women
- Current severe, uncontrolled systemic disease
- Known untreated or active central nervous system (CNS) metastases